Mrs Corazon Intano-arca, MD | |
8033 E. Ten Mile, Suite 101, Centerline, MI 48015 | |
(586) 977-2900 | |
(586) 977-2992 |
Full Name | Mrs Corazon Intano-arca |
---|---|
Gender | Female |
Speciality | General Practice |
Location | 8033 E. Ten Mile, Centerline, Michigan |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1821198243 | NPI | - | NPPES |
104294015 | Medicaid | MI | |
3506356272 | Other | BCBSM | |
4294015 | Medicaid | MI | |
3506356272 | Other | MI | BCBSM |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208D00000X | General Practice | 4301032630 (Michigan) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mrs Corazon Intano-arca, MD 8033 E 10 Mile Rd, Suite 101, Center Line, MI 48015-1427 Ph: (586) 977-2900 | Mrs Corazon Intano-arca, MD 8033 E. Ten Mile, Suite 101, Centerline, MI 48015 Ph: (586) 977-2900 |
News Archive
When ethanol prices at the pump rise for whatever reason, it becomes economically advantageous for drivers of dual-fuel vehicles to fill up with gasoline.
Makers of approved drugs and biologics generally are meeting their regulatory obligations and complete their postmarketing studies in a timely manner, according to a study released today by the U.S. Food and Drug Administration.
Bristol-Myers Squibb Company and ZymoGenetics, Inc. (NASDAQ:ZGEN) announced that final results from a Phase 1b clinical trial in patients with hepatitis C (HCV) treated with PEG-Interferon lambda, a new class of interferon, in combination with ribavirin will be presented at the American Association for the Study of Liver Diseases (AASLD) annual meeting October 30–November 3, 2009, in Boston.
Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, announced today that the first patient has been enrolled in the CYPRESS study, which will assess clinical outcomes in a broad range of patients with coronary artery disease who take dual anti-platelet therapy after receiving a CYPHER Sirolimus-eluting Coronary Stent. The procedure was performed by Patrick Flaherty, D.O., Arkansas Heart Hospital in Little Rock, AK.
› Verified 9 days ago